Cargando…

Marked Decrease Over Time in Conversion Surgery After Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma

Background: Active surveillance for low-risk papillary microcarcinoma (PMC) of the thyroid is an accepted and safe management strategy. However, some patients undergo conversion surgery after the initiation of active surveillance for various reasons. We investigated the reasons for conversion surger...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Takahiro, Miyauchi, Akira, Ito, Yasuhiro, Kudo, Takumi, Kanemura, Nobuaki, Sano, Tsutomu, Kawano, Shiori, Yamamoto, Masatoshi, Fujishima, Makoto, Masuoka, Hiroo, Higashiyama, Takuya, Kihara, Minoru, Miya, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891222/
https://www.ncbi.nlm.nih.gov/pubmed/32664805
http://dx.doi.org/10.1089/thy.2020.0319
_version_ 1783652656319823872
author Sasaki, Takahiro
Miyauchi, Akira
Ito, Yasuhiro
Kudo, Takumi
Kanemura, Nobuaki
Sano, Tsutomu
Kawano, Shiori
Yamamoto, Masatoshi
Fujishima, Makoto
Masuoka, Hiroo
Higashiyama, Takuya
Kihara, Minoru
Miya, Akihiro
author_facet Sasaki, Takahiro
Miyauchi, Akira
Ito, Yasuhiro
Kudo, Takumi
Kanemura, Nobuaki
Sano, Tsutomu
Kawano, Shiori
Yamamoto, Masatoshi
Fujishima, Makoto
Masuoka, Hiroo
Higashiyama, Takuya
Kihara, Minoru
Miya, Akihiro
author_sort Sasaki, Takahiro
collection PubMed
description Background: Active surveillance for low-risk papillary microcarcinoma (PMC) of the thyroid is an accepted and safe management strategy. However, some patients undergo conversion surgery after the initiation of active surveillance for various reasons. We investigated the reasons for conversion surgery and whether and how they changed over time. Methods: We enrolled 2288 patients with PMC who underwent active surveillance. Of these, 162 (7.1%) underwent conversion surgery >12 months after initiating active surveillance due to disease progression (57 patients), patient preference (43 patients), physician preference (31 patients), other associated thyroid or parathyroid diseases (24 patients), and other reasons (7 patients). We analyzed cumulative conversion rates not only in the whole cohort but also in the first three major subsets based on the reasons for surgery. We also divided our whole cohort into two groups based on the period of active surveillance commencement: the first-half group (February 2005–November 2011; 561 patients) and the second-half group (December 2011–June 2017; 1727 patients). Results: The criteria for PMC progression did not differ between the first- and second-half groups. The proportion of female patients in the physician preference group was significantly higher than that in the disease progression and the patient preference groups. Tumor size at surgery was larger, and tumor volume-doubling rate was higher in the disease progression group than in the other two groups. Patients in the second-half group were significantly less likely to undergo conversion surgery than those in the first-half group. Furthermore, conversion surgery rates in the second-half group were significantly lower than those in the first-half group in the patient preference, physician preference, and disease progression groups. Conclusions: Patients with PMC in the second-half group were significantly less likely to undergo conversion surgery than those in the first-half group regardless of the reason. This is probably because data accumulation of favorable outcomes with active surveillance significantly contributed to physicians' confidence and patients' trust and understanding of this disease.
format Online
Article
Text
id pubmed-7891222
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Mary Ann Liebert, Inc., publishers
record_format MEDLINE/PubMed
spelling pubmed-78912222021-02-19 Marked Decrease Over Time in Conversion Surgery After Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma Sasaki, Takahiro Miyauchi, Akira Ito, Yasuhiro Kudo, Takumi Kanemura, Nobuaki Sano, Tsutomu Kawano, Shiori Yamamoto, Masatoshi Fujishima, Makoto Masuoka, Hiroo Higashiyama, Takuya Kihara, Minoru Miya, Akihiro Thyroid Thyroid Cancer and Nodules Background: Active surveillance for low-risk papillary microcarcinoma (PMC) of the thyroid is an accepted and safe management strategy. However, some patients undergo conversion surgery after the initiation of active surveillance for various reasons. We investigated the reasons for conversion surgery and whether and how they changed over time. Methods: We enrolled 2288 patients with PMC who underwent active surveillance. Of these, 162 (7.1%) underwent conversion surgery >12 months after initiating active surveillance due to disease progression (57 patients), patient preference (43 patients), physician preference (31 patients), other associated thyroid or parathyroid diseases (24 patients), and other reasons (7 patients). We analyzed cumulative conversion rates not only in the whole cohort but also in the first three major subsets based on the reasons for surgery. We also divided our whole cohort into two groups based on the period of active surveillance commencement: the first-half group (February 2005–November 2011; 561 patients) and the second-half group (December 2011–June 2017; 1727 patients). Results: The criteria for PMC progression did not differ between the first- and second-half groups. The proportion of female patients in the physician preference group was significantly higher than that in the disease progression and the patient preference groups. Tumor size at surgery was larger, and tumor volume-doubling rate was higher in the disease progression group than in the other two groups. Patients in the second-half group were significantly less likely to undergo conversion surgery than those in the first-half group. Furthermore, conversion surgery rates in the second-half group were significantly lower than those in the first-half group in the patient preference, physician preference, and disease progression groups. Conclusions: Patients with PMC in the second-half group were significantly less likely to undergo conversion surgery than those in the first-half group regardless of the reason. This is probably because data accumulation of favorable outcomes with active surveillance significantly contributed to physicians' confidence and patients' trust and understanding of this disease. Mary Ann Liebert, Inc., publishers 2021-02-01 2021-02-12 /pmc/articles/PMC7891222/ /pubmed/32664805 http://dx.doi.org/10.1089/thy.2020.0319 Text en © Takahiro Sasaki et al., 2021; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Thyroid Cancer and Nodules
Sasaki, Takahiro
Miyauchi, Akira
Ito, Yasuhiro
Kudo, Takumi
Kanemura, Nobuaki
Sano, Tsutomu
Kawano, Shiori
Yamamoto, Masatoshi
Fujishima, Makoto
Masuoka, Hiroo
Higashiyama, Takuya
Kihara, Minoru
Miya, Akihiro
Marked Decrease Over Time in Conversion Surgery After Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma
title Marked Decrease Over Time in Conversion Surgery After Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma
title_full Marked Decrease Over Time in Conversion Surgery After Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma
title_fullStr Marked Decrease Over Time in Conversion Surgery After Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma
title_full_unstemmed Marked Decrease Over Time in Conversion Surgery After Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma
title_short Marked Decrease Over Time in Conversion Surgery After Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma
title_sort marked decrease over time in conversion surgery after active surveillance of low-risk papillary thyroid microcarcinoma
topic Thyroid Cancer and Nodules
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891222/
https://www.ncbi.nlm.nih.gov/pubmed/32664805
http://dx.doi.org/10.1089/thy.2020.0319
work_keys_str_mv AT sasakitakahiro markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT miyauchiakira markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT itoyasuhiro markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT kudotakumi markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT kanemuranobuaki markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT sanotsutomu markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT kawanoshiori markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT yamamotomasatoshi markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT fujishimamakoto markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT masuokahiroo markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT higashiyamatakuya markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT kiharaminoru markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma
AT miyaakihiro markeddecreaseovertimeinconversionsurgeryafteractivesurveillanceoflowriskpapillarythyroidmicrocarcinoma